SCHEMBL4765779

SCHEMBL4765779

O=C(Nc1ccc2c(c1)CCN(C1CCC1)CC2)c1cccc(-n2cccn2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 4/20 0.50
SMN1; SMN2 Q16637 5/20 0.45
KMT2A Q03164 5/20 0.45
NPC1 O15118 5/20 0.45
RAB9A P51151 5/20 0.45
HTT P42858 3/20 0.45
NFKB1 P19838 2/20 0.45
NFKB2 Q00653 2/20 0.45
RELA Q04206 2/20 0.45
ROCK2 O75116 1/20 0.44
GAA P10253 2/20 0.44
TP53 P04637 1/20 0.44
KDM4E B2RXH2 2/20 0.44
TEK Q02763 1/20 0.43
KAT6A Q92794 1/20 0.43
MEN1 O00255 2/20 0.42
MAPT P10636 2/20 0.42
KCNH2 Q12809 1/20 0.42
ALDH1A1 P00352 3/20 0.41
LMNA P02545 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4769682 0.91 HRH3 (0.54) HRH3SMN1; SMN2NPC1RAB9AHTT
SCHEMBL4767846 0.86 ROCK2 (0.54) HRH3SMN1; SMN2KMT2ANPC1RAB9A
SCHEMBL4765200 0.84 HRH3 (0.61) HRH3SMN1; SMN2NPC1RAB9AHTT
SCHEMBL4765219 0.84 KDM4E (0.56) HRH3SMN1; SMN2KMT2ARAB9AKDM4E
SCHEMBL4764985 0.82 RAB9A (0.64) HRH3SMN1; SMN2KMT2ANPC1RAB9A
SCHEMBL4768310 0.81 SMN1; SMN2 (0.48) HRH3SMN1; SMN2KMT2ANPC1RAB9A
SCHEMBL4772670 0.80 NPC1 (0.71) SMN1; SMN2KMT2ANPC1RAB9AHTT
SCHEMBL4772154 0.80 NPC1 (0.52) HRH3SMN1; SMN2KMT2ANPC1RAB9A
SCHEMBL4767344 0.80 TDP1 (0.58) HRH3SMN1; SMN2KMT2ANPC1RAB9A
SCHEMBL4776860 0.80 TP53 (0.50) HRH3SMN1; SMN2KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1713778-B1 BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS GLAXO GROUP LTD (GB) 2008-01-16 EP claimed
US-20070060566-A1 Benzazepine derivatives as histamine h3 antagonists GLAXO GROUP LIMITED (GB) 2007-03-15 US claimed
EP-1713778-B1 BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS GLAXO GROUP LTD (GB) 2008-01-16 EP disclosed
EP-1713778-B1 BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS GLAXO GROUP LTD (GB) 2008-01-16 EP disclosed
US-20070060566-A1 Benzazepine derivatives as histamine h3 antagonists GLAXO GROUP LIMITED (GB) 2007-03-15 US disclosed
US-20070060566-A1 Benzazepine derivatives as histamine h3 antagonists GLAXO GROUP LIMITED (GB) 2007-03-15 US disclosed
US-20070060566-A1 Benzazepine derivatives as histamine h3 antagonists GLAXO GROUP LIMITED (GB) 2007-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060566-A1 Benzazepine derivatives as histamine h3 antagonists HRH3, HRH4, HRH1 HRH3 1/4885SMN1; SMN2 2487/4885KMT2A 99/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.